Navigation Links
Taiho Pharmaceutical présente une demande d'homologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
Date:2/26/2013

TOKYO, 27 février 2013 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. a annoncé le 27 février avoir présenté le 26 février une demande d'homologation pour la fabrication et la commercialisation du nouvel agent antitumoral nucléoside administré par voie orale, le TAS-102 (mélange de Trifluorothymidine [FTD] et de tipiracil hydrochloride[TPI]), auprès du Ministère japonais de la Santé publique et du Travail. Taiho Pharmaceutical cherche à obtenir l'homologation pour le TAS-102 de l'indication contre le cancer colorectal récurrent à un stade avancé, non résécable.

La demande d'homologation se base sur les résultats de l'essai clinique de phase II (Étude 10040030) effectué dans 20 centres médicaux au Japon. C'est un essai à répartition aléatoire, mené en double insu pour comparer le TAS-102 à un placébo. Il porte sur 172 patients souffrant de cancer colorectal récurrent à un stade avancé, non résécable et réfractaire aux chimiothérapies standard d'au moins deux régimes contenant un mélange de fluoropyrimidine, d'irinotécan et d'oxaliplatine. Selon les résultats, le groupe à qui le TAS-102 a été administré a vu son taux de survie s'améliorer (durée médiane de survie globale : 9 mois contre 6,6 mois) et le risque de mortalité significativement réduire (HR : 0.56, p=0.0011). L'effet secondaire au médicament CTCAE de niveau 3 ou plus le plus fréquemment rapporté est la neutropénie. La diarrhée, la fatigue, la nausée et autres effets secondaires de niveau 3 n'ont pas dépassé les 10 %. Taiho Pharmaceutical mène actuellement un essai clinique mondial de phase III portant sur le TAS-102 sur une population similaire souffrant d'un cancer colorectal (RECOURSE
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
2. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
4. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
5. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
6. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
7. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
8. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
9. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
10. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
11. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015  Eli Lilly and Company (NYSE: ... announced cash tender offer for up to $1.6 billion aggregate ... Holders of notes who tendered, and did not validly ... New York City time, on May 27, 2015 ... by Lilly, are eligible to receive the total consideration. The ...
(Date:5/28/2015)... 28, 2015  Maetrics ( http://maetrics.com ), a leading ... wrapped up a successful conference, "The cost of non-compliance -- ... today in Zurich . ... its Switzerland -based team, experts provided ... Technology field to an exclusive local audience. The event ...
(Date:5/28/2015)... -- This report analyzes the worldwide markets for Intraocular Lenses ... Standard Intraocular Lenses, and Premium Intraocular Lenses. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2World Intraocular Lenses Industry 2World Intraocular Lenses Industry 3World Intraocular Lenses Industry 4World Intraocular Lenses Industry 5World Intraocular Lenses Industry 6World Intraocular Lenses Industry 7World Intraocular Lenses Industry 8World Intraocular Lenses Industry 9World Intraocular Lenses Industry 10World Intraocular Lenses Industry 11World Intraocular Lenses Industry 12World Intraocular Lenses Industry 13World Intraocular Lenses Industry 14World Intraocular Lenses Industry 15World Intraocular Lenses Industry 16World Intraocular Lenses Industry 17World Intraocular Lenses Industry 18World Intraocular Lenses Industry 19World Intraocular Lenses Industry 20World Intraocular Lenses Industry 21World Intraocular Lenses Industry 22World Intraocular Lenses Industry 23World Intraocular Lenses Industry 24World Intraocular Lenses Industry 25World Intraocular Lenses Industry 26
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, announced data from a recently ... oral dose formulation for LX4211, a dual inhibitor of ... Results from the study demonstrated that administration of ...
... Jan. 5, 2011 The pharmaceutical industry,s steep ... strategy and development executives to uncover opportunities for ... combination therapies with branded products to extend patent ... products can extend a therapeutic advantage and become ...
Cached Medicine Technology:Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 2Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 3Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 4Report Highlights Successful Strategies for Bringing FDC Products to Market 2
(Date:5/29/2015)... Mediaplanet has joined forces with Raw Elements ... importance of proper sun protection. The print component of ... circulation of approximately 250,000 copies and an estimated readership ... through a vast social media strategy, and across a ... explore the digital version of the campaign, click ...
(Date:5/29/2015)... Ca (PRWEB) May 29, 2015 ... pain consultations with specialists, physical therapy, and injections ... experiencing mid back and/or lower back pain, Healthpointe ... epidural injections for herniated discs, disc protrusions and ... . , Healthpointe’s team of renowned surgeons ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The ... giving patients a long-lasting impression on what modern dentistry ... VisitandCare.com is on a mission to revolutionize the perception ... with a high-class Wellness & Spa. , The ... world’s most successful medical tourism agencies and ...
(Date:5/29/2015)... MN (PRWEB) May 29, 2015 As ... Patio and Metro series outdoor saunas have increased in ... landscaping projects, and work at summer cottages. While ... piqued interest in summer projects a few weeks earlier ... suburban communities with smaller lot sizes tend to prefer ...
(Date:5/29/2015)... 29, 2015 Vulvodynia is defined as ... significant physical, sexual, and psychological distress. Women’s ... Vulvodynia. The actual diagnosis is often made on the ... realize that this problem can be very troublesome to ... these symptoms, they need to schedule and appointment with ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2
... Liberator Medical,Holdings, Inc. (OTC Bulletin Board: LBMH.OB) reported ... 2007 sales, which is thus far,the highest sales ... the Company,s ongoing continuous targeted advertising effort., ... our November,sales, we believe that in our first ...
... near crowded roadways face more than 50% risk of breathing ... Children with asthma who are exposed to traffic pollution are ... says a study that looked at children in the Mexican ... United States. , "Major cities along the northern and ...
... 13 The Ensign,Group, Inc. (Nasdaq: ENSG ... of,skilled nursing, rehabilitative care services and assisted living,companies, ... two skilled,nursing facilities in California and one assisted ... of approximately $12.8 million., (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ...
... part of its ongoing,global campaign to lower drug prices ... worldwide, AIDS Healthcare Foundation,(AHF) today responded to a modest ... Cipla, on three of its antiretroviral drugs to,fight HIV/AIDS. ... AHF-led,advocacy campaign aimed at pressuring Cipla to lower its ...
... in patients battling stomach cancer , , THURSDAY, Dec. 13 ... sunitinib (Sutent), which fights stomach tumors, can also create ... , All patients taking sunitinib, but especially those ... and treatment for high blood pressure and other signs ...
... Pro Bowler and TODAY,correspondent Tiki Barber spoke publicly for ... affects such a wide range of people in,different circumstances ... he told Meredith Vieira this morning on TODAY., ... founding,member and president, also appeared on TODAY to discuss ...
Cached Medicine News:Health News:Liberator Medical Supply Exceeds Projected November Sales 2Health News: Traffic Pollution Hurts Asthmatic Kids' Lungs 2Health News:The Ensign Group, Inc. Acquires Assets of Three Previously Leased Facilities 2Health News:Cipla Offers Modest AIDS Drug Price Cut: 'Not Nearly Enough,' says AHF 2Health News:Cipla Offers Modest AIDS Drug Price Cut: 'Not Nearly Enough,' says AHF 3Health News:New Cancer Drug Tied to Heart Problems 2Health News:New Cancer Drug Tied to Heart Problems 3Health News:New Cancer Drug Tied to Heart Problems 4Health News:Former NFL Star Tiki Barber and CURE Founder Susan Axelrod Speak Out About Epilepsy on TODAY Show 2
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-2000...
Prolactin EIA Reproductive Markers 025-BC-1037...
... (17aOHP) is produced by both the ... has relatively little progestational activity, it ... it is the,immediate precursor to 11-desoxycortisol ... 21-hydroxylation of 17aOHP,measurement of 17aOHP is ...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: